You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202191 - 202200 of 207728 results
  1. IGF::OT::IGF OTHER FUNCTIONS- NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DIAGNOSIS, STAGING, AND TREATMENT

    SBC: ARkival Technology Corporation            Topic: NCI

    This technology introduces a new non-invasive, biopsy-adjunct with a MNP platform for targeted tumor delivery. It employs closely sized magnetic nanoparticles (CS-MNP's) for determining their concentration and spatial distribution in tumor vasculatures asmeasured by magnetic resonance imaging (MRI). The relationship between CS-MNP size and Vibrating Sample Magnetometer (VSM) measurement foll ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. IGF::OT::IGF OTHER FUNCTIONS RandD- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

    SBC: Enlyton, Ltd.            Topic: NCI

    Surgical resection of malignant tumors is the single most effective therapy for cancer. Long-term patient outcomes are strongly determined by the extent to which the surgeon can completely remove all diseased tissues. Present cancer imaging and detectionmethods often fail to provide a clear picture of the extent of disease. SPECT (single photon emission computed tomography) is a sizeable market ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually in the US. However, ~40% of patients will be, or become resistant to AIs. If sensitivity to AI can be re-established in patients that have become resistant, this would be a major step forward in treati ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

    SBC: BENEVIR BIOPHARM, INC.            Topic: NCI

    There are ~20,000 cases per year of glioblastoma in the U.S., and median survival time is only 15 months. The integration of two technologies to create an optimized oncolytic virus for glioblastoma is proposed. The resulting virus is triply armed: (1) it has a clinically proven mechanism and enhanced abilities to evade the immune system; (2) it disrupts the physical barrier between glioblastoma ce ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. TARGETING BMP SIGNALING WITH TP-0413

    SBC: TOLERO PHARMACEUTICALS, INC.            Topic: NCI

    TP-0413 is a novel small molecule inhibitor of the BMP pathway that has significant potential to be developed to treat anemia of cancer. Anemia of cancer is cytokine driven and results in the up-regulation of a liver hormone called hepcidin through the function of BMP receptors. Increased hepcidin levels result in the storage of iron in cellular compartments resulting in low serum iron and anemia. ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    The objective of this contract is to develop INTI-1, an Anti-DEspR Therapeutic mAb and related Companion Diagnostic mAb, for use against DEspR+ cancers lacking effective therapies, such as Pancreatic Adenocarcinoma (PCa), Glioblastoma Multiforme (GBM) andTriple Negative Breast Cancer TNBC . Anti-DEspR mAbs have identified DEspR+ tumor cells (TCs), cancer stem cells (esCs) and tumor vascular endot ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. OTHER FUNCTIONS: CELL-FREE PRODUCTION OF SITE-SPECIFICALLY PHOSPHORYLATED PROTEINS PSC CODE AN11

    SBC: Rana Bioscience, Inc.            Topic: NCI

    SBIR Topic 312 Generation and Qualification of site-specific Post-translationally Modified Proteins for Use as Calibrators in Pharmacodynamic (PD) Assays

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. IGF::OT::IGF OTHER FUNCTIONS SILOAM PHASE I, TOPIC 309, LOW VOLUME, ULTRA-SENSITIVE IMMUNODIAGNOSTIC SYSTEM

    SBC: SILOAM BIOSCIENCES            Topic: NCI

    The goal of this SBIR project is to develop a low lost, ultrasensitive immunodiagnostic system for measuring multiple cancer biomarkers rapidly with small amount of samples. This system can be used by physicians to improve cancer early detection, diagnosis, prognosis and treatment monitoring. Cancer biomarkers have been widely used for cancer early detection and diagnosis. Assay with multiple c ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. IGF::OT::IGF OTHER FUNCTIONS PHARMASEQ PHASE I, TOPIC 309, MULTIPLEX PROSTATE CANCER SERUM ASSAY ON RFID P-CHIPS

    SBC: Pharmaseq, Inc            Topic: NCI

    The project is aimed at the development of a cost effective, serum-based multiplex assay for early detection of clinically significant forms of prostate cancer. The assay utilizes metal-enhanced flourescence to provide an ultra-sensitive immunoassay for three cancer markers: alpha-methylacyl coenzyme A racemase (AMACR), annexin A3 and zinc alpha-glycoprotein (ZAG). The fluorescence enhancement is ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. IGF::OT::IGF OTHER FUNCTIONS GENOME PHASE I, TOPIC 309, LABEL FREE MULTIVARIATE CANCER DIAGNOSIS

    SBC: GENOME DATA SYSTEMS, INC.            Topic: NCI

    Breast cancer is a leading cause of malignancies in women, resulting in almost 200,000 new cases every year. In approximately one third of breast cancer patients, malignant cells spread to distant organs and cause metastatic tumors. Tumor progression, metastatic spread and patient prognosis depends on proteins present in cancerous cells. A number of proteins whose over-activation and impaired down ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government